Kornimate/medical-research-clean huggingface dataset:
growth hormone deficiency in adults (ghda)

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in japan. the aim of this trial is to demonstrate superiority of the effect of nn-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with growth hormone deficiency in adults (ghda).


Eligibility criteria:
inclusion criteria: * subjects with diagnosed ghd * if the subject has a history of treatment of treatment for a tumour of pituitary or peripheral site, two years or more must have passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded * appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies exclusion criteria: * subject with a history of acromegaly * subject with diabetes mellitus * subject suffering from malignancy * several medical conditions
procalung: project on cancer of the lung

Conditions: Locally Advanced Lung Carcinoma

Summary: procalung is a national registry collecting radiation treatment parameters of patients having lung cancer that extends to mediastinal lymph nodes. the project includes a peer review activity. the purpose of this public health program is similar to an audit whose objective is to promote quality of radiation oncology in belgium. it is run by institut jules bordet on behalf of the college of physicians for radiotherapy centers of the belgian health federal public service, in close collaboration with the belgian cancer registry. all belgian radiotherapy centers are invited to participate in procalung but their participation is not mandatory. the centers who accept to participate show a commitment to quality assurance as the radiotherapy-treatment-related parameters they generate will be analyzed to establish national statistics. it includes a peer-review process based on international guidelines for mediastinal nodes delineations given for informational purposes. the public interest program also collects technical parameters as they were planned and delivered during the course of chest radiation treatment. this includes the delineations of tumors, nodes and chest organs on simulation-ct images, pet/ct images, chest-ct images and the clinical information related to the lung cancer. results/statistics will be published at the end of the project.


Eligibility criteria:
inclusion criteria: * histologically confirmed nsclc only * locally advanced disease (stage iii) with positive mediastinal nodes * pet/ct staged * curative intent radiotherapy * chemotherapy (cht): without, sequential cht - radiotherapy (rt) (max 2 cycles), concurrent (± induction cht) * prescription dose ≥ 60 gy (eqd2) exclusion criteria: * prior history of thoracic rt * malignant pleural effusion * history of malignancy in the last 3 years, except basal-cell skin cancer and intra-epithelial neoplasia * progression after induction chemotherapy * use of concurrent targeted, immunomodulating or anti-angiogenic agents except if the patient is included in a clinical trial

Keywords: nsclc radiation therapy mediastinal adenopathy quality assurance delineation national registry
ultra-low-dose chest ct for hht

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: this study aims to develop a novel ultra-low dose chest ct technology for use in hereditary hemorrhagic teleangiectasia (hht) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.


Eligibility criteria:
inclusion criteria: * ages 1 to 17 years * diagnosed with positive hht causing mutations or based on curacao criteria exclusion criteria: * acute respiratory distress * unstable cardiovascular status * pneumothorax, hemoptysis * pulmonary edema * pulmonary emboli * fractured ribs or other chest trauma * recent bronchoscopy * lung transplantation
contrast induced acute kidney in patients with acute stroke

Conditions: Stroke, Acute

Summary: computed tomographic angiography (cta) is recommended for identifying eligible patient with acute ischemic stroke (ais) to receieve endovascular treatment. we are going to conduct this prospective corhot study to observe if sequential use contrast in cta examination and in endovascular treatment will cause acute kidney injury.


Eligibility criteria:
inclusion criteria: * all patients who are suspected with ais. * non-contrast head ct excludes intracranial hemorrhage. exclusion criteria: * lacking of pre-cta creatinine * lacking of post-angiography creatinine with 24-48 hours
study on the effect of cervical mobilization on motor function and pressure pain threshold in pain free individuals

Conditions: Neck Pain

Summary: passive accessory cervical mobilization is widely used as a clinical approach to the management of musculoskeletal pain of spinal origin. the purpose of the study is to determine if passive cervical mobilization can improve motor function in situations where motor performance is not impaired by the presence of pain.

cervical mobilization has been shown to elicit effects on pain perception, autonomic function and motor function in subjects who experience musculoskeletal pain. the improvement in motor function may be a direct effect of the treatment or secondary to a hypoalgesic effect. this study aims to demonstrate whether it is possible to alter motor function following joint mobilization, in situations where motor performance is not impaired by pain.

Eligibility criteria:
inclusion criteria: * no history of neck or back pain over the last six months * without any previous experience with spinal manual therapy techniques exclusion criteria: * history of musculoskeletal or rheumatologic conditions * any kind of spinal surgery * dizziness * previous trauma to the cervical spine * neurological signs or symptoms

Keywords: physical therapy pain threshold electromyography musculoskeletal manipulation neck muscles
chronic cardiovascular risk outpatient management in south asians using digital health technology

Conditions: Cardiovascular Risk Factor; Insulin Resistance; PreDiabetes; Diabetes; Coronary Artery Disease; Hypertension; Prehypertension; Dyslipidemias

Summary: this platform will enable investigation the cardiovascular risk reduction and the increase in participant engagement in their heart-healthy goals, through the use of virtual care/telemedicine with a digital platform that connects them to their own doctors, nurses, and dietitians.

the study will use telemedicine and the mobile health capabilities of smartphones to facilitate communication of medical goals set by the treating physician to the subject in between clinic visits, and to assess the daily medical and lifestyle change compliance of enrolled stanford subjects and provide virtual health coaching, as needed, to subjects to achieve said goals. how patients comply with their specific medical and lifestyle goals all affect their cardiovascular health, yet largely go unmeasured. these can now be measured with a notification-based system in which subject-entered activity, medication compliance, and dietary reporting data will be collected, assessed, and trigger appropriate responses by the subject's care team, which includes their physician, nurse, dietitian, and assigned health coach. we aim to collect this subject-reported activity and cardiovascular care plan compliance data to provide much more quantitative data on type, duration, and intensity of daily activities and compliance with the medication regimens of enrolled subjects. the study will compare anthropometric cardiovascular risk biomarkers testing at the initial visit and after 3 months, in subjects utilizing the healthpals digital platform plus the standard ssathi clinic visits, versus subjects receiving only ssathi clinic visits.

Eligibility criteria:
inclusion criteria: * adult smartphone users exclusion criteria: * subjects who do not own a smartphone or cannot access their mobile health data * patients unable to read english, as the initial version of the research app will be in english * participants who are children (under 18 years old) * participants who are pregnant women * participants who are economically and educationally disadvantaged, decisionally impaired, homeless people, or employees of stanford university will be excluded due to being of a vulnerable population. * participants who express active chest pain or shortness of breath in their first clinic visit and are clinically deemed to require an emergency room evaluation will be excluded * participants who have inability or unwillingness to use or connect to data services for app messaging * participants with an upcoming surgical procedure (for instance, a clinic visit as part of preoperative evaluation) that will significantly impair or block their ability to follow the chronic disease management program during the study period * participants who have pre-existing participation in another clinical research protocol.

Keywords: south asian cardiovascular risk reduction metabolic disorders lifestyle modifications
efficacy of a pvp-i fluoride varnish

Conditions: Dental Caries

Summary: the purpose of the study is to determine the efficacy of advantage anti-caries varnish. single-center, double-blind, controlled phase 2 study with parallel groups of children. subjects will be stratified by early childhood education center and then randomized to receive either test varnish or control varnish topically to the teeth. treatment will be administered quarterly for up to 24 months. the primary outcome is surface-level primary molar caries increment (d2-4mfs) at 24- months post baseline.

objectives: primary - to determine if advantage anti-caries varnish (test varnish) is superior to a control varnish containing only fluoride in the prevention of new caries lesions. secondary * to establish that the response of child participants to the test varnish was not inferior to the control varnish

Eligibility criteria:
inclusion criteria: 1. the subject's parent or legal guardian must provide signed and dated informed consent (parent permission form). 2. the subject's parent or legal guardian of the subject must be willing and able to comply with study requirements. 3. the subject is aged 60-84 months at the time of enrollment. 4. the subject must be in good general health as evidenced by parent report. exclusion criteria: 1. known allergy to iodine 2. known allergy to seafood 3. known hypersensitivity to fluoride varnish 4. diagnosis of thyroid disease 5. chronic, prophylactic use of antibiotics 6. treatment with another investigational drug or other intervention within 30 days preceding the baseline visit.

Keywords: sodium fluoride povidone iodine varnish
forest bathing intervention for persons living with dementia and family carers

Conditions: Dementia; Caregiver Mental Health

Summary: this study assessed the feasibility and acceptability of a forest bathing intervention for people living with dementia and their family carers, and examined its effectivness on care burden and quality of life by comparing to an art activty programme as control group.


Eligibility criteria:
inclusion criteria: * for family careivers: * taking care of a family member living with dementia in the community, * for people living with dementia: * clinical diagnosis of mild to moderate dementia exclusion criteria: * for both: * unable to communicate in chinese or cantonese * unable to participate meaningfully in group activities due to intellectual disability, visual impairment, hearing impairment, or other health conditions, were excluded.

Keywords: forest bathing
physiotherapy or acupuncture for lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: work-related upper extremity disorders are common problems in working populations in western countries. lateral epicondylitis (le) or tennis elbow is the most frequent type of soft tissue syndrome of the elbow, with an annual incidence of four to seven cases per 1000 patients in general practice, and as high as 15 % of workers in highly repetitive hand task industries. le is a painful condition, leading to loss of function of the affected limb. therefore it can have a major impact on the patient's work and personal life. if untreated, it persists for an average of six to 24 months and associated with significant sickness absence in 5 % of affected working-aged adults. the cost is therefore high, both in terms of loss of productivity and health care utilization. many treatments have been advocated in the management of le, possibly implying that much is unknown about its etiology and how it best should be treated. systematic reviews have failed to draw any firm conclusions as to what treatment is most effective in managing this condition. over the past 10 years acupuncture has gained wider acceptance for treating pain, by both clinicians and consumers of health, and there is some evidence suggesting that acupuncture treatment is effective in of acute symptoms in le. a recent study supports that also elbow manipulation have a short-term relief of acute symptoms in le, especially when combined with eccentric exercise. our study will therefore explore the clinical effectiveness of physiotherapy versus acupuncture treatment of le, compared with watchful waiting.

the study design is three armed and randomized, single blinded. the study aims, in a pilot stydy, to test if physiotherapy or acupuncture treatment of lateral epicondylitis, compared with watchful waiting, is useful means in pain relief for patients with lateral epicondylitis.

Eligibility criteria:
inclusion criteria: * lateral epicondylitis le (duration \> 2 weeks) * unilateral localization * individuals with average pain of nrs 4 or higher during the last week prior to screening * aged between 18 and 67 years * written informed consent exclusion criteria: * corticosteroid injections during the last 4 weeks * diseases of the central or peripheral nervous system * inflammatory rheumatic diseases * radio-ulna or radio humeral osteoarthritis * unwilling to participate

Keywords: physiotherapy manual therapy acupuncture eccentric exercise
premixed vs sequential injections of lidocaine and bupivacaine for supraclavicular brachial plexus block in patients undergoing arteriovenous fistula creation

Conditions: Premixed; Sequential; Lidocaine; Bupivacaine; Supraclavicular Brachial Plexus Block; Arteriovenous Fistula

Summary: this study aims to compare premixed and sequential injections of lidocaine and bupivacaine for supraclavicular brachial plexus block in patients undergoing arteriovenous fistula creation.

hemodialysis is the common treatment for end-stage renal disease (esrd) condition which improves quality of life and survival rate for this group of patients. arteriovenous fistula (avf) creation is the vascular access technique that provides long-term vascular access for hemodialysis patients. ultrasound-guided supraclavicular brachial plexus block (scbpb) is a widely accepted and effective technique for avf creation procedures. it provides analgesia, sympathetic blockade, optimal surgical conditions, and adequate duration of postoperative block that prevents arterial spasm and graft thrombosis. it offers higher blood flow in the radial artery and arteriovenous fistula than is achieved with infiltration anesthesia. lipid-soluble local anesthetics (la) such as ropivacaine and bupivacaine are generally more potent and have a significantly longer duration of action as well as a more prolonged onset of action compared to intermediate-potency drugs such as lignocaine, mepivacaine, and prilocaine. a combination of two las is often used in regional blocks to utilize the different clinical properties of the drugs to achieve a faster onset and longer block duration.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiology (asa) physical status iii. * undergoing arteriovenous fistula creation. exclusion criteria: * allergy to local anesthetics. * body mass index (bmi) ≥ 35 kg/m2. * preoperative neurological deficit. * neuromuscular disorder. * psychiatric disorder. * coagulation disorder. * congestive heart failure. * pregnancy. * infection at the site of block.
pegylated liposomal doxorubicin or epirubicin in neoadjuvant or adjuvant chemotherapy for breast cancer.

Conditions: Breast Cancer

Summary: pegylated liposomal doxorubicin or epirubicin in neoadjuvant or adjuvant chemotherapy for breast cancer.

this study is an real-world, multicenter, case control study about comparing pegylated liposomal doxorubicin efficacy and safety of epirubicin in neoadjuvant and adjuvant chemotherapy for breast cancer. as this trial is a retrospective real-world study, investigator have given patients the dose of trial drugs based on real-world principles of diagnosis and treatment and their clinical experience. this trial only collects and analyzes patients' clinical medications, and does not interfere with patients' real-world diagnosis and treatment. a total of 1050 breast cancer patients are collecting from seven centers. 200 cases in neoadjuvant and 850 cases in adjuvant group. the follow-up examinations and assessment of the subjects were followed by real-world medical treatment routines and the visits were completed according to the routine of treatment. related check and assessments and collect the following data: follow-up 3years or until the disease recurs (whichever occurs first). adverse events: remission or stability of adverse events caused by follow-up to treatment in the adjuvant treatment group, follow-up for 3 years or until recurrence of the disease in the neoadjuvant treatment group (whichever first occurred).

Eligibility criteria:
inclusion criteria: 1. female; 2. patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy; 3. chemotherapy regimen recommended by the guidelines for drugs containing anthracycline; 4. patients whose chemotherapy regimen contains pegylated liposomal doxorubicin or epuroxorubicin; 5. age :18 -70; 6. patients with lvef ≥ 50%. exclusion criteria: 1. patients with occult breast cancer. 2. patients receiving two or more anthracyclines during neoadjuvant or adjuvant chemotherapy; 3. patients who have previously received other chemotherapy regimens; 4. patients with other malignant tumors in the past 5 years (except for cured cervical carcinoma in situ and basal cell carcinoma of the skin); 5. patients complicated with severe infection and in need of treatment; 6. pregnant or lactating women.

Keywords: invasive breast cancer neoadjuvant adjuvant anthracycline
predicting mri abnormalities with longitudinal data of the whitehall ii substudy

Conditions: Cognitive Impairment; Dementia; Affective Disorders

Summary: follow-up study within the whitehall ii study, selecting 800 participants for further neuropsychological, clinical and imaging (mri) examinations to examine brain structure and function in relation to age-related diseases and the modifiable and non-modifiable factors affecting resilience against and vulnerability to adverse brain changes.

a total of 6035 civil servants participated in the whii phase 11 clinical examination in 2012-2013. a random sample of 800 of these participants was included in a sub-study comprising an mri brain scan, a detailed clinical and cognitive assessment, and collection of blood and buccal mucosal samples for the characterisation of immune function and associated measures. data collection for this sub-study started in 2012 and was completed by in 2016. the participants, for whom social and health records have been collected since 1985, were between 60-85 years of age at the time the mri study started. the pre-specified clinical and cognitive assessment protocols, the state-of-the-art mri sequences and latest pipelines for analyses of this sub-study have been published and are attached to this application.

Eligibility criteria:
inclusion criteria: * member of whitehall ii cohort attending at ucl for phase 11 exclusion criteria: * not suitable for mri, travelling to oxford, seriously physically ill

Keywords: epidemiology magnetic resonance imaging diffusion tensor imaging white matter functional mri connectome resting state brain networks neuropsychology
break-through infection following mpox vaccination

Conditions: Mpox

Summary: the purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.

a target trial emulation study that tries to emulate the sequential specification of a target trial will be conducted measuring and controlling confounders when there is a common cause of vaccination and outcome event. participants will be provided with a quick response (qr) code to access the redcap study platform, which will guide them to the enrolment process. if the participant accepts and meets all the inclusion and none of the exclusion criteria, they will be directed to a baseline survey to self-collect sociodemographic data and information regarding risk factors, sexual behaviour, vaccination, and exposure to mpox. newly vaccinated participants will be matched 1:1 to unvaccinated controls. the matching will be performed based on the site of recruitment, and self-reported baseline sexual health and practices. vaccinated and unvaccinated participants will be matched on variables associated with the probability of infection. follow-up will include regular surveys every month from the index date (i.e., enrolment date in the unvaccinated group, or vaccination date for the vaccinated group), to collect data on change on risk factors, sexual behaviour in the past month, vaccination status, and exposure to mpox. the participant will be asked to self-report if they develop symptoms suggestive of mpox, and the study platform will direct them to a specific mpox infection survey. for each participant, follow-up will end at the earliest of the following events: mpox infection, voluntary withdraw, or the end of the study period. a health record review will be conducted to corroborate the diagnosis of new cases and to provide validity to the self-report.

Eligibility criteria:
inclusion criteria: 1. individuals aged 18 years or older. 2. individuals with general risk factors for mpox infection, as currently defined by the local guidelines for vaccination. these risk factors include at least one of the following items: * individual-reported use of hiv pre-exposure prophylaxis (prep). * individual-reported chemsex practices * individual-reported multiple sexual partners. * individuals with a history of a sexually transmitted infection (sti) in the past year. * individuals living with hiv infection. 3. signature of informed consent. exclusion criteria: 1. unable to provide signature of informed consent. 2. past infection with monkeypox. 3. past smallpox vaccination.

Keywords: monkeypox mpox vaccine intradermal mpox vaccine mpox